A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Selonsertib (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms STELLAR 4
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Apr 2018 According to a Gilead Sciences media release, data from this trial is expected in the first half of 2019.
    • 25 Mar 2018 This trial has been completed in Portugal.
    • 23 Feb 2018 Planned End Date changed from 1 Oct 2023 to 1 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top